14 completed, 2 active not recruiting, 2 recruiting. 18 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 14, Active not recruiting 2, Recruiting 2 |
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Linvoseltamab, Daratumumab - High Risk Smoldering Multiple Myeloma (HR-SMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 270 | 2026-05-21 | 2026-10-21 |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma Daratumumab, Dexamethasone, Lenalidomide - Smoldering Plasma Cell Myeloma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 288 | 2019-09-16 | 2026-08-19 |
| A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Daratumumab SC: daratumumab + rHuPH20 - Smoldering Multiple Myeloma | Phase 3 | Completed | Janssen Research & Development, LLC | 390 | 2017-11-07 | 2026-06-08 |
| A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies canakinumab - Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers | Phase 3 | Completed | Novartis Pharmaceuticals | 31 | 2014-11-03 | 2020-05-19 |
| Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Clinical Observation, Lenalidomide, Quality-of-Life Assessment - Light Chain Deposition Disease, Smoldering Multiple Myeloma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 226 | 2011-01-24 | 2026-10-01 |
| American Ginseng in Treating Patients With Fatigue Caused by Cancer American ginseng, placebo - Chronic Myeloproliferative Disorders, Fatigue | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 364 | 2008-10-01 | 2017-02-09 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression Maintenance with lower doses of lenalidomide and dexamethasone - Multiple Myeloma | Phase 3 | Completed | PETHEMA Foundation | 120 | 2007-05-01 | 2013-07-31 |
| Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose - Anemia, Leukemia | Phase 3 | Completed | Mayo Clinic | 502 | 2006-01-01 | 2011-05-17 |
| Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain educational intervention, Titrated pain management, questionnaire administration - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Vanderbilt-Ingram Cancer Center | 98 | 2005-05-01 | 2012-09-06 |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Lenalidomide - DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 460 | 2004-12-15 | 2026-08-26 |
| Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer darbepoetin alfa, epoetin alfa - Anemia, Leukemia | Phase 3 | Completed | Jonsson Comprehensive Cancer Center | 14 | 2003-08-01 | 2020-08-03 |
| Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment ondansetron, placebo - Chronic Myeloproliferative Disorders, Leukemia | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 100 | 2000-10-01 | 2016-07-06 |
| Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment caspofungin acetate, liposomal amphotericin B - Cancer | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 2000-08-01 | 2013-01-18 | |
| Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Fragmin, placebo - Cervical Cancer, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Jonsson Comprehensive Cancer Center | 2000-04-01 | 2020-08-03 | |
| St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer St. John's wort - Chronic Myeloproliferative Disorders, Fatigue | Phase 3 | Completed | Memorial Sloan Kettering Cancer Center | 1999-12-01 | 2013-01-18 | |
| Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients liposomal amphotericin B - Cancer | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 115 | 1999-06-01 | 2012-09-24 |
| Treatment for Chronic Pain in Patients With Advanced Cancer dextromethorphan hydrobromide, morphine sulfate - Chronic Myeloproliferative Disorders, Leukemia | Phase 3 | Completed | NCIC Clinical Trials Group | 87 | 1998-06-11 | 2020-04-03 |
Multiple Myeloma (14) · Hodgkin Disease (11) · Immunoblastic Lymphadenopathy (11) · Immunoglobulin Light-chain Amyloidosis (11) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Lymphoma, Follicular (11) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Large-Cell, Anaplastic (11) · Lymphoma, Large-Cell, Immunoblastic (11) · Lymphoma, Mantle-Cell (11) · Lymphoma, Non-Hodgkin (11) · Lymphoma, T-Cell, Cutaneous (11) · Monoclonal Gammopathy of Undetermined Significance (11) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (11) · Burkitt Lymphoma (10)
Blood Protein Disorders (18) · Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Paraproteinemias (17) · Cardiovascular Diseases (14) · Hemorrhagic Disorders (14) · Hemostatic Disorders (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Vascular Diseases (14) · Chronic Disease (12) · Disease Attributes (12)
Lenalidomide (3) · Darbepoetin alfa (2) · Dexamethasone (2) · daratumumab (2) · liposomal amphotericin B (2) · Asian ginseng (1) · Calcium Dobesilate (1) · Caspofungin (1) · Dalteparin (1) · Dextromethorphan (1) · Early Intervention, Educational (1) · Epoetin Alfa (1) · Fentanyl (1) · Hypericum extract LI 160 (1) · Maintenance (1)
Alliance for Clinical Trials in Oncology (2) · Jonsson Comprehensive Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (2) · ECOG-ACRIN Cancer Research Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · INSYS Therapeutics Inc (1) · Janssen Research & Development, LLC (1) · Mayo Clinic (1) · NCIC Clinical Trials Group (1) · Novartis Pharmaceuticals (1) · PETHEMA Foundation (1) · Regeneron Pharmaceuticals (1) · Vanderbilt-Ingram Cancer Center (1)
United States (14) · France (3) · Spain (3) · Belgium (2) · Canada (2) · Czechia (2) · Germany (2) · Greece (2) · Hungary (2) · Israel (2) · Italy (2) · Japan (2) · Netherlands (2) · Poland (2) · Puerto Rico (2)
John A. Glaspy, MD, MPH (2) · Charles L. Loprinzi, MD (1) · David J. Straus, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Eduardo Bruera, MD (1) · Kent Sepkowitz, MD (1) · Larry Dillaha, MD (1) · Nancy Wells, DNSc, RN (1) · Natalie S Callander (1)
PMID 15459300, PMID 16710026, PMID 17397698, PMID 20473362, PMID 22480131, PMID 22511492, PMID 22571201, PMID 23902483, PMID 26668134, PMID 27020837, PMID 27402145, PMID 28826616, PMID 31652094, PMID 36067617, PMID 36999619, PMID 39652675, PMID 42747040
U10CA180820 (2), 2014 (1), 2016 (1), 2023 (1), 2025 (1), P30CA015083 (1), P30CA068485 (1), U10CA021115 (1), U10CA031946 (1), U10CA180821 (1), U24CA196172 (1)